Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Innovation Labs to Enhance Collaboration

24 de mayo de 2022 actualizado por: Larry Hawk, Ph.D., State University of New York at Buffalo

Controlled Evaluation of Innovation Labs for Enhancing Collaboration Among Early Career Scholars in the CTSA Network

We will conduct and evaluate the impact of two week-long Innovation Labs on collaboration attitudes and behavior among early career scholars. Applicants to each Innovation Lab will be screened and then randomized to either the Innovation Lab group or a control group.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

Building on the science of team science and preliminary work at the Buffalo and Vanderbilt CTSAs, we propose to work with our industry partner Knowinnovation to implement, assess, and disseminate an innovative and promising method for stimulating and nurturing new transdisciplinary research teams across the CTSA Program consortium: Innovation Labs. We will focus on early career investigators, have well-developed expertise, and will benefit from developing transdisciplinary collaborations. This work will further advance the field by taking a strong translational science approach to identify and test "best practices". To accomplish this, we will critically evaluate the impact of Innovation Labs in two preliminary randomized controlled trials (RCTs). In collaboration with NCATs and broad input from the CTSA network, we will develop a clinical and translational research grand challenge focus for each Innovation Lab. A diverse applicant pool of early career investigators invited from every CTSA hub in the consortium will be reviewed, and top applicants will be randomized to a 5-day residential Innovation Lab or "treatment as usual" control group (n=25/group/RCT). Measures of process and outcome will be collected from the application phase through 12-month follow-up and aggregated across the two RCTs. Given the preliminary nature of the work and an emerging consensus regarding the science of team science, primary outcomes will be measures of the depth and breadth of participants collaborative networks and attitudes towards collaboration, which we predict will be enhanced in the Innovation Lab group compared to the treatment as usual control group. We will also gather initial data on the degree to which Innovation Labs result in increased transdisciplinary collaborative output, including grant proposals, publications, and presentations. The significance of this work is clear: We aim to advance clinical and translational science by critically evaluating a potential "best practice" method for catalyzing collaborations and enhancing innovative translational research, a core goal of the CTSA Program. Our initial RCTs target an important segment of the workforce and begin the process of dissemination across the CTSA network, setting the stage for much broader implementation and impact.

Tipo de estudio

Intervencionista

Inscripción (Actual)

94

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • Buffalo, New York, Estados Unidos, 14260
        • University at Buffalo

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Completion of application and baseline assessment.

For randomization:

  • Faculty at a NIH CTSA hub institution or regional partner.
  • Early stage investigators (NIH-defined as "within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)") who are emerging as independent scholars.
  • Applications were reviewed for the above criteria and ranked by committee according to goodness of fit with the topic of the Innovation Lab, the quality and quantity of academic productivity and collaboration, and contribution to diversity of perspectives among Lab participants (e.g., biomedical and social/psychological, basic and applied). Top-ranked applicants were retained for randomization to the Innovation Lab group or control group.

All applicants (including 94 randomized ppts and 13 ppts who were not randomized) were encouraged to remain in the study and complete the follow-up assessments.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Innovation Lab Group
Randomized to attend the Innovation Lab
An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
Sin intervención: Control Group
Randomized to NOT attend the Innovation Lab

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline MATRICx Benefits Scale
Periodo de tiempo: through study completion, an average of 15 months
Self-report: Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) - Motivator scale
through study completion, an average of 15 months
Change from Baseline MATRICx Threats Scale
Periodo de tiempo: through study completion, an average of 15 months
Self-report: Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) - Threats scale
through study completion, an average of 15 months
Change from Baseline Transdisciplinary Orientation Scale
Periodo de tiempo: through study completion, an average of 15 months
Self-report: 12-item Transdisciplinary Orientation scale (TDO; Misra, Stokols, & Cheng, 2015)
through study completion, an average of 15 months
Change from Baseline Collaboration Network Size
Periodo de tiempo: through study completion, an average of 15 months
Objective size of network of collaborators from published articles on PubMed
through study completion, an average of 15 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline Grants Submitted
Periodo de tiempo: through study completion, an average of 15 months
Self-Reported Number of New Grants Submitted
through study completion, an average of 15 months
ILab met goal - new collab
Periodo de tiempo: 3 months
The Lab met the goal of forming new transdisciplinary collaborations (ILab group only)
3 months
ILab met goal - novel proposals
Periodo de tiempo: 3 months
The Lab met the goal of developing novel grant proposals on long-lasting lifestyle interventions (ILab group only)
3 months
ILab - recommend
Periodo de tiempo: 3 months
I would recommend an Innovation Lab to a colleague (ILab group only)
3 months
ILab - positive impact
Periodo de tiempo: 3 months
My experience in the Innovation Lab will have a positive impact on my work at my home institution (ILab group only)
3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de agosto de 2017

Finalización primaria (Actual)

12 de julio de 2019

Finalización del estudio (Actual)

25 de junio de 2020

Fechas de registro del estudio

Enviado por primera vez

19 de mayo de 2022

Primero enviado que cumplió con los criterios de control de calidad

24 de mayo de 2022

Publicado por primera vez (Actual)

27 de mayo de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de mayo de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

24 de mayo de 2022

Última verificación

1 de mayo de 2022

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY00001360

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Innovation Lab

3
Suscribir